LY255283, a competitive leukotriene B4 receptor antagonist, is used in leukotriene receptor research along with other selective leukotriene receptor agonists and antagonist to identify and differentiate the physiological and cell signaling effects of the leukotriene B4 receptor on processes such as paclitaxel resistance in MCF-7/DOX breast cancer cells, monocyte-derived dendritic cell chemotaxis, and 5-lipoxygenase activity and interleukin-8 production in human neutrophils. LY255283 may be used to help verify that an observed process or cell event is leukotriene B4 receptor-dependent. Antagonists of the chemotactic and inflammatory lipoxygenase product leukotriene B4 (LTB4) have been potential drug development targets for several years.1,2 The tetrazole LY255283 is a competitive antagonist of the BLT2 receptor. It displaces radiolabeled LTB4 from guinea pig lung membrane, with an IC50 of about 100nM.3 LY255283 exhibits IC50 values of ~950nM and >10uM at human recombinant BLT2 and BLT1 receptors, respectively.4 LY255283 inhibits eosinophil chemotaxis by 80% at a concentration of 10uM, and inhibits the binding of radiolabeled LTB4 to eosinophil membranes with an IC50 of 260nM.1 Synonyms: 1-[5-ethyl-2-hydroxy-4-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]phenyl]-ethanone CAS No: 117690-79-6 Molecular Formula: C19H28N4O3 Molecular Weight: 360.5 Appearance: Pale yellow solid Purity: 98% Melting Point: 168-170C(dec) Solubility: 100mM in DMSO and to 25mM in Ethanol Storage: 4C
Molekulargewicht:
360.5
Reinheit:
98%
Formulierung:
Pale yellow solid
CAS Nummer:
[117690-79-6]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
